EZH2 (11) Mouse Monoclonal Antibody
SIGMA/415M-1
Product Type: Chemical
Immunohistochemistry EZH2 (11) on breast carcinoma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | 11, monoclonal |
| conjugate | unconjugated |
| control | breast carcinoma, prostate adenocarcinoma, tonsil |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG1 |
| manufacturer/tradename | Cell Marque™ |
| packaging | bottle of 1.0 mL predilute (415M-17) |
| bottle of 7.0 mL predilute (415M-18) | |
| vial of 0.1 mL concentrate (415M-14) | |
| vial of 0.5 mL concentrate (415M-15) | |
| vial of 1.0 mL concentrate (415M-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 |
| visualization | nuclear |
| General description: | Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) in order to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer types. Hyperactivation of EZH2, either by overexpression or mutations, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma. EZH2 overexpression has been reported in non-small cell lung cancers and lymphoma.The EZH2 protein is rarely detected in normal breast duct epithelium and in normal and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas, although only in 20% (1/5) of small lymphocytic lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma have not been shown to express this protein. Recent studies also have demonstrated EZH2 is aberrantly over-expressed in pediatric rhabdomyosarcoma, independent of the histological subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations | ||||
| Legal Information: | Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany | ||||
| Linkage: | EZH2 Positive Control Slides, Product No. 415S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
||||
| Quality: |
|
| RIDADR | NONH for all modes of transport |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |